Buradasınız

Anasayfa » Content

KRONİK KARACİĞER HASTALARINDA HEPATİT A AŞISI YAPILMALI MI ?

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Hepatitis A virus (HAV) infection which commonly is seen in childhood in developing countries and may be responsible for fulminant hepatic failure. In this study, antibody to HAV in the patients with chronic liver disease was studied retrospectively. Vaccination of these patients who are under risk is recommended. Results.- Fifty-eight of 171 patients had had anti HAV IgG (+) and 113 of 171 had anti HAV IgG(-). Acute HAV infection was occurred in 7 patients during follow-up. The mean age of the anti HAV IgG (+) and (-) groups was 9.9± 4.6 and 8.7± 4.3 years respectively. Conclusion.- Although in our country, the prevalence of exposure to HAV changes with age and regions (54.5% at 3-10 years), there is a decrease in the ratio with improvement of hygienic conditions. Because the possibility of HAV infection in patients with chronic liver disease during adolescent or elderly is more dangerous, passive immunization of these patients is recommended.
Bookmark/Search this post with
Abstract (Original Language): 
Gelişmekte olan ülkelerde daha çok çocukluk çağında geçirilen hepatit A enfeksiyonu kronik karaciğer hastalarında fülminan seyredebilmektedir. Risk altındaki bu hastaların aşı- lanması önerilmektedir. Retrospektif olarak yap ılan bu çalışmada kronik karaciğer hastalar ındaki anti HAV IgG (+)’liği irdelenmiştir. Bu amaçla araştırılan 171 hastanın 58’inde (%34) anti HAV IgG (+), 113’ünde (%66) anti HAV IgG (-) idi. Yedi olgu (%4) ise izlem sü- releri içinde hastalığı akut enfeksiyon şeklinde geçirmişti. Anti HAV IgG (+) ve (-) olan olgular ın yaş ortalaması sırasıyla 9,9±4,6 ve 8,7± 4,3 yaş idi. Her ne kadar ülkemizde anti-HAV prevalans ı yaşa ve yöreye göre değişmekte ise de (3- 10 yaşta %54,5), hijyen koşullarının düzelmesi ile bu oranõn giderek azaldığı görülmektedir. Enfeksiyon riskinin ileri yaşlara kayması kronik karaciğer hastalarındaki riski daha da arttı- racağından, bu hastaların aşılanması uygundur.
FULL TEXT (PDF): 
PDF icon arastirmax-kronik-karaciger-hastalarinda-hepatit-asisi-yapilmali-mi.pdf
  • 1
7-9
  • Turkish

REFERENCES

References: 

1. Yazõgõ NA, Balistreri WF. Acute and chronic viral
hepatitis. In: Suchy FJ, Sokol RJ, Balistreri WF (eds).
Liver Disease in Children. 2nd. Ed. Philadelphia,
Lippincott Williams & Wilkins, 2001; 367-427.
2. Sokal EM, Bortolotti F. Update on prevention and
treatment of viral hepatitis in children. Curr Opin Pediatr
1999; 11: 384-389.
3. Szmuness W, Diestang JL, Robert HP. The prevalence of
antibody to hepatitis A antigen in various parts of the
world: A pilot study. Am J Epidemiol 1977; 106: 392-
398.
4. Ayhan Akbulut. HAV enfeksiyonu. İçinde: Kõlõçturgay
K, Badur S (yazarlar). Viral Hepatit 2001. Birinci basõm.
İstanbulViral Hepatitle Savaşõm Derneği, 2001; 57-84.
5. Diago M, Lujan M, Garcia V et al. Prevalence of antihepatitis
A in patients with chronic liver disease.
Gastroenterol Hepatol 1998; 21: 324-326.
6. Manns MP, Schuler A. Risk of hepatitis A superinfection
in patients with underlying liver disease. Acta
Gastroenterol Belg 1998; 61: 206-209.
7. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and
immunogenicity of hepatitis A vaccine in patients with
chronic liver disease. Hepatology 1998; 27: 881-886.
8. Lee SD, Chan CY, Yu MI, et al. Safety and
immunogenicity of inactivated hepatitis A vaccine in
patients with chronic liver disease. J Med Virol 1997; 52:
215-218.
9. Vento S, Garofano T, Renzini C, et al. Fulminant
hepatitis associated with hepatitis A virus superinfection
in patients with chronic hepatitis C. N Engl J Med 1998;
338: 286-290.
10. Keeffe EB. Is hepatitis A more severe in patients with
chronic hepatitis B and other chronic liver diseases? Am
J Gastroenterol 1995; 90: 201-205.
11. Lemon SM. Type A viral hepatitis: new developments in
an old disease. N Engl J Med 1985; 313: 1059-1067.
12. Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N,
Attamasirikul K. Acute hepatitis-A superinfection in
HBV carriers, chronic liver disease related to HBV or
HCV. Ann Trop Med Parasitol 1999; 93: 745-751.
13. Keeffe E. Hepatitis A in patients with chronic liver
disease-severity of illness and prevention with
vaccination. J Viral Hepat 2000; 7: 15-17.
14. Sung JJ. Epidemiplogy of hepatitis A in Asia and
experience with the HAV vaccine in Hong Kong. J Viral
Hepat 2000; 1: 27-28.
15. Lee S. Hepatitis A vaccination in patients with chronic
liver disease in Taiwan. J Viral Hepat 2000; 1: 19-21.
16. Dumot JA, Barnes DS, Younossi Z. Immunogenicity of
hepatitis A vaccine in decompensated liver disease. Am J
Gastroenterol 1999; 94: 1601-1604.
17. Daly P. Hepatitis C and the British Columbia experience
with hepatitis A vaccination. J Viral Hepat 2000; 7: 23-
25.
18. Tsang SW, Sung JJ. Inactivated hepatitis A vaccine in
Chinese patients with chronic hepatitis B infection.
Aliment Pharmacol Ther 1999; 13: 1445-1449.
19. Nebbia G, Giacchino R, Soncini R, Ramaccioni V,
Timitilli A, Zanetti AR. Hepatitis A vaccination in
chronic carriers of hepatitis B virus. J Pediatr 1999; 134:
784-785.
20. Olive G, Buti M, Ignacio Esteban J, Cotrina M, Esteban
R, Guardia J. Prevalence and incidence of hepatitis A in
patients with hepatitis B and C. Med Clin 2000; 115:
254-255.
21. Akbulut A, Kõlõç SS, Felek S, Akbulut H. The prevalence
of hepatitis A in the Elazõğ region. Turk J Med Sci 1996;
26: 375-378.
22. Poyraz Ö, Sümer H, Öztop Y, Saygõ G, Sümer Z. Sivas
yöresinde genel toplumda hepatit A, B, C virüs
belirleyicilerinin araştõrõlmasõ. Enfeksiyon Dergisi 1995;
9: 175-178.

Thank you for copying data from http://www.arastirmax.com